Q&A: AbbVie VP Lin On Filling Humira's Big Shoes In Immunology
Executive Summary
AbbVie's Shao-Lee Lin talks about drug candidates that the company hopes will extend its legacy in immunology, which is built on the foundation of the world's top-selling biopharma product Humira.
You may also be interested in...
Westlake Village BioPartners Closes Two VC Funds Totaling $500m
A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.
AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
AbbVie's JAK1 inhibitor upadacitinib bested the company's blockbuster Humira in the largest and longest trial to date – on both efficacy and safety – perhaps alleviating concerns about cardiovascular events.